Prelude Therapeutics (PRLD) Registration Filing summary

Company overview and business model

• Precision oncology company focused on developing novel cancer medicines for underserved patients, leveraging expertise in cancer biology, medicinal chemistry, and clinical development.

• Pipeline includes kinase inhibitors, targeted protein degraders, and degrader antibody conjugates, with several programs in clinical and preclinical stages.

• Collaborates with AbCellera Biologics on early-stage discovery programs targeting tumor-specific antigens.

• Incorporated in Delaware in 2016, with principal offices in Wilmington, Delaware.

Financial performance and metrics

• In November 2025, received $25 million from Incyte for 6,250,000 shares of non-voting common stock at $4.00 per share.

• Received an additional $35 million upfront payment from Incyte for an exclusive option on a JAK2V617F inhibitor program.

• Potential future payments from Incyte could reach up to $910 million, including milestones and royalties, if the option is exercised.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by the selling stockholder; all proceeds go to the selling stockholder.

• Company bears registration and related offering expenses, while the selling stockholder pays commissions and legal fees related to their sales.